Metastatic 4S neuroblastoma with excellent outcome in Saudi cancer center

References

1. 1.↵
   1. Cohn SL,
   2. Pearson SDJ,
   3. London WB,
   4. Monclair T,
   5. Ambros PF,
   6. Brodeur GM, et al.

   The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 2009; 27: 289–297.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Park JR,
   2. Bagatell R,
   3. Cohn SL,
   4. Pearson AD,
   5. Villablanca JG,
   6. Berthold F, et al.

   Revisions to the international neuroblastoma response criteria: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol 2017; 35: 2580–2587.

   OpenUrlCrossRef
3. 3.↵
   1. D’Angio GJ,
   2. Evans AE,
   3. Koop CE.

   Special pattern of widespread neuroblastoma with a favourable prognosis. Lancet 1971; 1: 1046–1049.

   OpenUrlPubMedWeb of Science
4. 4.↵
   1. Strother DR,
   2. London WB,
   3. Schmidt ML,
   4. Brodeur GM,
   5. Shimada H,
   6. Thorner P, et al.

   Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children’s Oncology Group study P9641. J Clin Oncol 2012; 30: 1842–1848.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Baker DL,
   2. Schmidt ML,
   3. Cohn SL,
   4. Maris JM,
   5. London WB,
   6. Buxton A, et al.

   Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med 2010; 363: 1313–1323.

   OpenUrlCrossRefPubMedWeb of Science
6. 6.↵
   1. Nuchtern JG,
   2. London WB,
   3. Barnewolt CE,
   4. Naranjo A,
   5. McGrady PW,
   6. Geiger JD, et al.

   A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children’s Oncology Group study. Ann Surg 2012; 256: 573–580.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Avanzini S,
   2. Buffoni I,
   3. Gigliotti AR,
   4. Parodi S,
   5. Paraboschi I,
   6. Inserra A, et al.

   Resection of primary tumor in stage 4S neuroblastoma: a second study by the Italian Neuroblastoma Group. Pediatr Surg Int 2021; 37: 37–47.

   OpenUrl
8. 8.↵
   1. Taggart DR,
   2. London WB,
   3. Schmidt ML,
   4. DuBois SG,
   5. Monclair TF,
   6. Nakagawara A, et al.

   Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age. J Clin Oncol 2011; 29: 4358–4364.

   OpenUrlAbstract/FREE Full Text
9. 9.
   1. Nickerson HJ,
   2. Matthay KK,
   3. Seeger RC,
   4. Broduer Gm,
   5. Shimada H,
   6. Prez C, et al.

   , Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children’s Cancer Group study. J Clin Oncol 2000; 18: 477–786.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Hsu LL,
    2. Evans AE,
    3. D’Angio Gj

    . Hepatomegaly in neuroblastoma stage 4s: criteria for treatment of the vulnerable neonate. Med Pediatr Oncol 1996; 27: 521–528.

    OpenUrlCrossRefPubMedWeb of Science
11. 11.↵
    1. Schleiermacher G,
    2. Rubbie H,
    3. Hartman O,
    4. Bergeron C,
    5. Chastagner P,
    6. Mechinaud F, et al.

    Treatment of stage 4s neuroblastoma--report of 10 years’ experience of the French Society of Paediatric Oncology (SFOP). Br J Cancer 2003; 89: 470–476.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Elimam NA,
    2. Atra AA,
    3. Fayea NY,
    4. Al-Asaad TG,
    5. Khattan TM,
    6. Al-Sulami GA, et al.

    Stage 4S neuroblastoma, a disseminated tumor with excellent outcome. Saudi Med J 2006; 27: 1734–1736.

    OpenUrlPubMed